Zobrazeno 1 - 10
of 262
pro vyhledávání: '"A. Kramchaninov"'
Autor:
А. К. Dynjak
Publikováno v:
Oncologia i radiologia Kazakhstana. 55:51-54
Relevance: Many issues of cancer epidemiology are not resolved, the incidence remains high. In 1960, Kazakhstani scientists studied the regional features of skin cancer. Many questions and conclusions which modern scientists have come to in the world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87ba2122c8589984fc8729d982ba3ecc
https://doi.org/10.52532/2521-6414-2020-1-55-51-54
https://doi.org/10.52532/2521-6414-2020-1-55-51-54
Autor:
Fedor V. Moiseenko, Mikhail Yu. Fedyanin, Nikita M. Volkov, Nuriniso Kh. Abduloeva, Natalya V. Levchenko, Vyacheslav A. Chubenko, Albina S. Zhabina, Maria L. Stepanova, Mikhail M. Kramchaninov, Elizaveta V. Artemeva, Vladimir M. Moiseyenko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 1, Pp 47-55 (2022)
Rationale: Non-small cell lung cancer (NSCLC) is an aggressive disease with median survival of 1214 months in inoperable patients in the pre-immunotherapy era. Nowadays, under treatment with checkpoint inhibitors median survival is 1922 months. Howev
Externí odkaz:
https://doaj.org/article/8287edf3421a4498985c6a66a464a8e4
Autor:
Zakharov, Yuri D., Kuznetsov, Anton B., Kakabadze, Mikheil V., Sharikadze, Mevlud Z., Gavrilova, Anastasia A., Kramchaninov, Aleksei Yu.
Publikováno v:
In Cretaceous Research August 2021 124
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://doaj.org/article/7960a21c1a0a4a80b8f80fc55c3111e3
Autor:
Kramchaninov, A. Yu.1 (AUTHOR) alex-ligg@yandex.ru
Publikováno v:
Journal of Analytical Chemistry. Dec2021, Vol. 76 Issue 13, p1549-1557. 9p.
Autor:
Fedor V. Moiseyenko, Vitaliy V. Egorenkov, Mikhail M. Kramchaninov, Elizaveta V. Artemieva, Svetlana N. Aleksakhina, Maxim M. Holmatov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 2, Pp 339-343 (2019)
Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all rare BRAF substitutions. Proper cataloguing of drug-sensitive and -insensitive rare mutations remains a challenge, due to low occurr
Externí odkaz:
https://doaj.org/article/f3fe4fb603f74a8c8c7e0175c35ce4aa
Autor:
Lebedeva, Alexandra, Timokhin, Grigory, Ignatova, Ekaterina, Kavun, Alexandra, Veselovsky, Egor, Sharova, Margarita, Mileyko, Vladislav, Yakushina, Valentina, Kuznetsova, Olesya, Stepanova, Maria, Shilo, Polina, Moiseenko, Fedor, Volkov, Nikita, Plaksa, Igor, Isaev, Andrey, Gayryan, Margarita, Artemyeva, Elizaveta, Zhabina, Albina, Kramchaninov, Mikhail, Shamrikova, Valentina
Publikováno v:
Clinical & Experimental Medicine; Oct2023, Vol. 23 Issue 6, p2663-2674, 12p
Publikováno v:
Gornyi Zhurnal. :67-71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7de11df4030bd55c742bd488c71f44f7
https://doi.org/10.17580/gzh.2023.03.10
https://doi.org/10.17580/gzh.2023.03.10
Autor:
Dubinina, E. O.1 (AUTHOR) elenadelta@gmail.com, Kramchaninov, A. Yu.2 (AUTHOR), Silantyev, S. A.3 (AUTHOR), Bortnikov, N. S.1 (AUTHOR)
Publikováno v:
Petrology. Jul2020, Vol. 28 Issue 4, p374-388. 15p.
Autor:
M. L. Stepanova, O. A. Kuznetsovа, P. S. Shilo, F. V. Moiseenko, N. Kh. Abduloeva, E. V. Artemyeva, A. S. Zhabina, M. M. Kramchaninov, N. M. Volkov, I. A. Pokataev, A. A. Rumyantsev, I. L. Plaksa, M. A. Gairyan, A. A. Isaev, M. V. Ivanov, Yu. F. Sadykova, V. A. Mileiko, V. V. Shamrikova, E. V. Ledin, A. A. Tryakin, M. Yu. Fedyanin
Publikováno v:
Pelvic Surgery and Oncology. 12:26-35
Background. The use of targeted sequencing panels makes it possible to optimize and personalize the treatment strategy for cancer patients. Given the lack of a clear «portrait of the patient», the role of large panels (200 or more genes) in the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94de84342c21de6572b6facf4d1cd22e
https://doi.org/10.17650/2686-9594-2022-12-3-26-35
https://doi.org/10.17650/2686-9594-2022-12-3-26-35